Calcitonin News and Research RSS Feed - Calcitonin News and Research

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.
Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

An intestinal patch device containing insulin that can be swallowed in the form of a capsule, in development by researchers at University of California Santa Barbara, has demonstrated efficacy of blood glucose management in diabetic rats. This work is being presented Oct. 27 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29. [More]
TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016. [More]
Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show. [More]
EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF Diagnostics, the global in vitro diagnostics company, announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham, UK, 28-30 September. This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. Also on Stand 812, EKF will highlight the latest additions to its range of Stanbio liquid-stable, LiquiColor® and Liqui-UV® clinical chemistry reagents, including an assay for Procalcitonin - an important adjunct marker in the diagnosis of sepsis. [More]
MU researchers identify age-related cause of arterial dysfunction

MU researchers identify age-related cause of arterial dysfunction

With the world's elderly population expected to double by 2050, understanding how aging affects the body is an important focus for researchers globally. Cardiovascular disease, the No. 1 cause of death worldwide, often is associated with aging arteries that restrict blood flow. Now, University of Missouri researchers have identified an age-related cause of arterial dysfunction, a finding that could lead to future treatments for some forms of vascular disease. [More]
Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease. [More]
Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). [More]
Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine. [More]
CGRP monoclonal antibodies show promise in treating migraine

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
EKF introduces specific biomarker test for early sepsis identification

EKF introduces specific biomarker test for early sepsis identification

EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay. This new test enables the quantitative determination of PCT in serum samples, EDTA or lithium heparin plasma samples by latex enhanced immunoturbidimetric methodology. Procalcitonin is a marker for bacterial infection and sepsis and has been recognized as an important adjunct marker in the diagnosis of sepsis. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

Inflammatory diseases can occur simultaneously in distinct sites in the same patient, complicating treatment because a medication effective for one disorder may exacerbate the other. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Blocking a pain receptor in mice not only extends their lifespan, it also gives them a more youthful metabolism, including an improved insulin response that allows them to deal better with high blood sugar. [More]
Inflammation may accentuate age-related bladder function decline

Inflammation may accentuate age-related bladder function decline

Age-associated biochemical changes in the bladder may accentuate the inflammation associated with overactive bladder, study findings indicate. [More]
New studies may offer hope for people with migraine

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. [More]
Advertisement
Advertisement